Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/9/2025 | $280.00 → $255.00 | Outperform | Telsey Advisory Group |
| 4/3/2025 | $410.00 → $130.00 | Buy → Underperform | BofA Securities |
| 4/3/2025 | $200.00 | Buy → Neutral | Citigroup |
| 4/3/2025 | $420.00 → $280.00 | Outperform | Telsey Advisory Group |
| 3/24/2025 | $500.00 → $420.00 | Outperform | Telsey Advisory Group |
| 1/30/2025 | $261.00 → $374.00 | Sell → Neutral | Goldman |
| 1/13/2025 | $435.00 → $530.00 | Equal-Weight → Overweight | Morgan Stanley |
| 1/8/2025 | $383.00 → $515.00 | Equal Weight → Overweight | Barclays |
4 - RH (0001528849) (Issuer)
3 - RH (0001528849) (Issuer)
4 - RH (0001528849) (Issuer)
Telsey Advisory Group reiterated coverage of RH with a rating of Outperform and set a new price target of $255.00 from $280.00 previously
BofA Securities downgraded RH from Buy to Underperform and set a new price target of $130.00 from $410.00 previously
Citigroup downgraded RH from Buy to Neutral and set a new price target of $200.00
RH (NYSE:RH) has released its financial results for the first quarter ended May 3, 2025, in a shareholder letter from Chairman and Chief Executive Officer Gary Friedman, available on the Investor Relations section of its website at ir.rh.com. As previously announced, RH leadership will host a live conference call and audio webcast at 2:00 pm Pacific Time (5:00 pm Eastern Time) today. The live conference call may be accessed by dialing 800.715.9871 or 646.307.1963 for international callers (conference ID: 8284432). The call and replay can also be accessed via audio webcast at ir.rh.com. ABOUT RH RH (NYSE:RH) is a curator of design, taste and style in the luxury lifestyle market. The Co
RH (NYSE:RH) today announced that it will report financial results for the first quarter ended May 3, 2025, on Thursday, June 12, 2025, after market close. RH's first quarter fiscal 2025 financial results press release will include a shareholder letter from Chairman and Chief Executive Officer, Gary Friedman, highlighting the Company's continued evolution and recent performance. The shareholder letter and financial results will be posted to the Company's investor relations website at ir.rh.com. RH leadership will host a live conference call and audio webcast at 2:00 pm Pacific Time (5:00 pm Eastern Time) on June 12, 2025. The live conference call may be accessed by dialing 800.715.9871 or
RH announced today the appointment of Lisa Chi as President, Co-Chief Merchandising & Creative Officer reporting to RH Chairman & CEO Gary Friedman. Lisa will co-lead Product Development, Merchandising, Inventory Planning, Sourcing, Manufacturing, and Marketing, across the Company's Physical, Print, and Digital Platforms with Eri Chaya, RH President, Co-Chief Merchandising & Creative Officer and member of the RH Board of Directors. "We are honored to welcome Lisa back to Team RH as we continue to elevate and expand our product and platform," commented RH Chairman & CEO Gary Friedman. "Lisa's accomplishments while at Arhaus were impressive as she led the merchandising organization during a
10-Q - RH (0001528849) (Filer)
8-K - RH (0001528849) (Filer)
DEF 14A - RH (0001528849) (Filer)
Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/13/2021. Application Category: ANDA, Application Number: 213111, Application Classification:
Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/13/2021. Application Category: ANDA, Application Number: 213111, Application Classification:
Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/15/2021. Application Category: ANDA, Application Number: 213111, Application Classification: